BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:PF-08032562 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of PF-08032562\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07318805-9084@assetmemo.bio
DTSTAMP:20261121T005403Z
DTSTART;VALUE=DATE:20290414
DTEND;VALUE=DATE:20290415
SUMMARY:PF-08032562: Phase 1 readout est. (NCT07318805)
DESCRIPTION:PF-08032562\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Study to Learn About the Study Medicine Called PF-08032562 in Peopl
 e With Advanced or Metastatic Solid Tumors\nEstimated primary completion: 
 14 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pf-080
 32562#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07318805
URL:https://assetmemo.bio/drug/pf-08032562#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
